Autoimmune mechanisms and inflammation in obesity-associated type 2 diabetes, atherosclerosis, and non-alcoholic fatty liver disease

被引:0
|
作者
Yuanyuan Sun [1 ]
Xueting Shan [1 ]
Mingyang Li [1 ]
Yifan Niu [4 ]
Zhongxin Sun [5 ]
Xiang Ma [1 ]
Tao Wang [3 ]
Jufang Zhang [2 ]
Dong Niu [1 ]
机构
[1] Zhejiang A&F University,College of Animal Science and Technology & College of Veterinary Medicine, Key Laboratory of Applied Technology on Green
[2] Westlake University,Eco
[3] Nanjing Kgene Genetic Engineering Co.,Healthy Animal Husbandry of Zhejiang Province, Provincial Engineering Research Center for Animal Health Diagnostics & Advanced Technology, Zhejiang International Science and Technology Cooperation Base for Veterinary M
[4] Ltd,Department of Plastic and Aesthetic Surgery, Affiliated Hangzhou First People’s Hospital, School of Medicine
[5] Zhejiang University,College of Animal Sciences
[6] Reconstructive & Hand Microsurgery,Department of Plastic
[7] Ningbo NO.6 Hospital,undefined
关键词
Obesity; Chronic inflammation; Metabolic Diseases; Pathophysiology;
D O I
10.1007/s10142-025-01587-0
中图分类号
学科分类号
摘要
Obesity, characterized by the excessive accumulation of white adipose tissue, is a significant global health burden and a major risk factor for a range of diseases, including malignancies and metabolic disorders. Individuals with high visceral fat content are particularly susceptible to severe complications such as type 2 diabetes, cardiovascular diseases, and liver disorders. However, the pathogenesis of obesity-related metabolic diseases extends beyond simple adiposity. Chronic obesity triggers a prolonged inflammatory response, which leads to tissue fibrosis and sustained organ damage, contributing to multi-organ dysfunction. This review explores the autoimmune mechanisms and inflammatory pathways underlying obesity-induced type 2 diabetes, atherosclerosis, and non-alcoholic fatty liver disease, with an emphasis on their interrelated pathophysiology and the potential for therapeutic interventions.
引用
收藏
相关论文
共 50 条
  • [31] Non-alcoholic fatty liver disease and type 2 diabetes Management and treatment
    Puetzer, Jennifer
    Kahl, Sabine
    DIABETOLOGE, 2020, 16 (06): : 574 - 583
  • [32] Type 2 diabetes originated from non-alcoholic fatty liver disease
    Xiong, Xuelian
    Li, Xiaoying
    LIFE METABOLISM, 2023, 2 (01):
  • [33] Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity?
    Schroeder, Benjamin
    Kahl, Sabine
    Roden, Michael
    LIVER INTERNATIONAL, 2021, 41 : 105 - 111
  • [34] The prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus
    Heyens, Leen
    Robaeys, Geert
    Bielen, Rob
    Kockaerts, Yves
    Busschots, Dana
    JOURNAL OF HEPATOLOGY, 2020, 73 : S412 - S413
  • [35] Type 2 diabetes originated from non-alcoholic fatty liver disease
    Xuelian Xiong
    Xiaoying Li
    LifeMetabolism, 2023, 2 (01) : 10 - 12
  • [36] Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
    Resuli, B.
    Agaci, F.
    Kraja, B.
    Sema, K.
    Dhigoi, N.
    Kapia, M.
    Burda, I.
    DIABETOLOGIA, 2010, 53
  • [37] Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease
    Yilmaz, Yusuf
    Senates, Ebubekir
    Yesil, Atakan
    Ergelen, Rabia
    Colak, Yasar
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2014, 28 (03) : 328 - 331
  • [38] Non-alcoholic fatty liver disease and diabetes
    Reyes-Garcia, Rebeca
    Rozas-Moreno, Pedro
    Julio Llamoza-Torres, Camilo
    Mezquita-Raya, Pedro
    MEDICINA CLINICA, 2017, 148 (01): : 33 - 38
  • [39] Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
    Shao, Ning
    Kuang, Hong Yu
    Hao, Ming
    Gao, Xin Yuan
    Lin, Wen Jian
    Zou, Wei
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2014, 30 (06) : 521 - 529
  • [40] Non-alcoholic fatty liver disease and diabetes
    Hazlehurst, Jonathan M.
    Woods, Conor
    Marjot, Thomas
    Cobbold, Jeremy F.
    Tomlinson, Jeremy W.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (08): : 1096 - 1108